|View printer-friendly version|
Portola Pharmaceuticals to Webcast Corporate Update on January 9, 2018
Portola will provide clinical, regulatory and manufacturing updates on the Company’s first
To access the live investor webcast on
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the